Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

Monitoring of minimal residual disease (MRD) has become routine clinical practice in
frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and in many …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

Importance Minimal residual disease (MRD) refers to the presence of disease in cases
deemed to be in complete remission by conventional pathologic analysis. Assessing the …

The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …

Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL)
results in high cure rates in pediatric patients but is suboptimal in the treatment of adult …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

Measurable residual disease (MRD) is highly prognostic for relapse and overall survival
(OS) in acute lymphoblastic leukemia (ALL), although many patients with apparent “MRD …

Significant advances have been made in the last decade toward a better understanding of
the disease pathogenesis and the development of novel therapies that target specific …

Because a pediatric-inspired Group for Research on Adult Acute Lymphoblastic Leukemia
(GRAALL) protocol yielded a markedly improved outcome in adults with Philadelphia …